- Home
- EQR vs PODD Comparison
EQR vs PODD Comparison
Compare EQR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- PODD
- Stock Information
- Founded
- EQR 1993
- PODD 2000
- Country
- EQR United States
- PODD United States
- Employees
- EQR N/A
- PODD N/A
- Industry
- EQR Real Estate Investment Trusts
- PODD Medical/Dental Instruments
- Sector
- EQR Real Estate
- PODD Health Care
- Exchange
- EQR Nasdaq
- PODD Nasdaq
- Market Cap
- EQR 24.5B
- PODD 22.1B
- IPO Year
- EQR 1993
- PODD 2007
- Fundamental
- Price
- EQR $62.23
- PODD $319.08
- Analyst Decision
- EQR Buy
- PODD Strong Buy
- Analyst Count
- EQR 11
- PODD 18
- Target Price
- EQR $74.50
- PODD $337.06
- AVG Volume (30 Days)
- EQR 2.2M
- PODD 571.3K
- Earning Date
- EQR 10-28-2025
- PODD 11-06-2025
- Dividend Yield
- EQR 4.45%
- PODD N/A
- EPS Growth
- EQR 5.58
- PODD N/A
- EPS
- EQR 2.65
- PODD 3.32
- Revenue
- EQR $3,044,764,000.00
- PODD $2,359,500,000.00
- Revenue This Year
- EQR $4.96
- PODD $29.18
- Revenue Next Year
- EQR $3.84
- PODD $18.16
- P/E Ratio
- EQR $23.44
- PODD $95.88
- Revenue Growth
- EQR 4.40
- PODD 26.00
- 52 Week Low
- EQR $59.41
- PODD $226.50
- 52 Week High
- EQR $78.32
- PODD $353.50
- Technical
- Relative Strength Index (RSI)
- EQR 41.46
- PODD 49.89
- Support Level
- EQR $61.16
- PODD $312.05
- Resistance Level
- EQR $62.84
- PODD $322.58
- Average True Range (ATR)
- EQR 0.92
- PODD 9.00
- MACD
- EQR -0.08
- PODD 0.53
- Stochastic Oscillator
- EQR 30.11
- PODD 84.70
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.